A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)

Trial Profile

A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2016

At a glance

  • Drugs Midazolam (Primary)
  • Indications Seizures
  • Focus Registrational; Therapeutic Use
  • Acronyms ARTEMIS EMU
  • Sponsors Upsher-Smith
  • Most Recent Events

    • 11 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 May 2015 Planned primary completion date changed from 1 May 2015 to 1 Oct 2015, according to ClinicalTrials.gov record.
    • 08 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top